padeliporfin VTP

Phase 3Recruiting

0 views this week 0 watching⚡ Active📊Featured in Mid-Cap Catalyst Watch

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Transitional Cell Cancer of Renal Pelvis and Ureter

Conditions

Transitional Cell Cancer of Renal Pelvis and Ureter

Trial Timeline

Mar 22, 2021 → Jan 25, 2029

NCT ID

NCT04620239

About padeliporfin VTP

padeliporfin VTP is a phase 3 stage product being developed by ICON plc. for Transitional Cell Cancer of Renal Pelvis and Ureter. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04620239. Target conditions include Transitional Cell Cancer of Renal Pelvis and Ureter.

What happened to similar drugs?

0 of 8 similar drugs in Transitional Cell Cancer of Renal Pelvis and Ureter were approved

Approved (0) Terminated (3) Active (5)

🔄Vepugratinib + EV + PembrolizumabEli LillyPhase 3

❌AtezolizumabRochePhase 3

🔄vinflunine and best supportive careBristol Myers SquibbPhase 3

🔄UGN-101 instillationsUroGen PharmaPhase 3

🔄NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3

❌NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04620239	Phase 3	Recruiting	Mar 22, 2021	Jan 25, 2029	Transitional Cell Cancer of Renal Pelvis and Ureter

Competing Products

20 competing products in Transitional Cell Cancer of Renal Pelvis and Ureter

See all competitors

Product	Company	Stage	Hype Score
Enfortumab vedotin	Astellas Pharma	Phase 2	35
enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine	Astellas Pharma	Phase 1/2	36
Pemetrexed + Gemcitabine + Platinol	Eli Lilly	Phase 1/2	32
Vepugratinib + EV + Pembrolizumab	Eli Lilly	Phase 3	47
durvalumab and tremelimumab	AstraZeneca	Phase 2	35
Docetaxel + vandetanib + Placebo	AstraZeneca	Phase 2	35
MK-3475 and BCG	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	31
Everolimus + Everolimus + Paclitaxel	Novartis	Phase 2	27
Buparlisib	Novartis	Phase 2	35
BEZ235	Novartis	Phase 2	27
Atezolizumab	Roche	Phase 3	32
Gemcitabine + Cisplatin + Sunitinib Malate	Pfizer	Phase 2	27
Nivolumab/Ipilimumab	Bristol Myers Squibb	Phase 2	31
vinflunine and best supportive care	Bristol Myers Squibb	Phase 3	40
vinflunine	Bristol Myers Squibb	Phase 2	35
Dasatinib	Bristol Myers Squibb	Pre-clinical	26
Docetaxel + Oxaliplatin	Sanofi	Phase 2	35
Cabazitaxel	Sanofi	Phase 2/3	38
Rogaratinib (BAY1163877) + Chemotherapy	Bayer	Phase 2/3	35